PBM fitness as vehicle for disease management initiatives remains open question, FTC official says.
Executive Summary
PBM FITNESS FOR DISEASE MANAGEMENT QUESTIONED BY FTC OFFICIAL at a Food & Drug Law Institute conference in Washington, D.C. Sept. 4. While disease management "seems like an initiative that pharmaceutical companies are very well suited for, the question we've always had and still have is whether [pharmacy benefit managers] are really the right vehicle" for the initiative, Federal Trade Commission Bureau of Competition Assistant Director Michael McNeely said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth